Learn about Lynne's experiences as a caregiver of a person with Alzheimer's disease.
Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.
10.27.2008 - Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
10.23.2008 - Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
10.21.2008 - Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80